{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:38:46Z","timestamp":1767857926078,"version":"3.49.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.prrv.2018.12.001","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T22:11:03Z","timestamp":1545084663000},"page":"35-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Expert consensus on palivizumab use for respiratory syncytial virus in developed countries"],"prefix":"10.1016","volume":"33","author":[{"given":"Manuel S\u00e1nchez","family":"Luna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosco","family":"Paes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Cossey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Kugelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Dotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Rodr\u00edguez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Resch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Carbonell-Estrany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2018.12.001_b0005","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015. A systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2018.12.001_b0010","doi-asserted-by":"crossref","unstructured":"Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS; WHO RSV Vaccine Consultation Expert Group. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23\u201324 March 2015. Vaccine 2016;34:190\u2013197.","DOI":"10.1016\/j.vaccine.2015.05.093"},{"key":"10.1016\/j.prrv.2018.12.001_b0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Sim\u00f5es","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.prrv.2018.12.001_b0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(15)00255-6","article-title":"Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics","volume":"3","author":"Mazur","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2018.12.001_b0025","first-page":"1","article-title":"RSV recommendations unchanged after review of new data","volume":"38","author":"Munoz","year":"2017","journal-title":"AAP News"},{"key":"10.1016\/j.prrv.2018.12.001_b0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2018.12.001_b0035","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","volume":"134","author":"American","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2018.12.001_b0040","unstructured":"PICO Framework. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMHT0029906\/. Date last accessed: September 18 2018."},{"key":"10.1016\/j.prrv.2018.12.001_b0045","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford 2009 and 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. http:\/\/www.cebm.net\/. Date last accessed: June 19 2018."},{"key":"10.1016\/j.prrv.2018.12.001_b0050","unstructured":"GRADE working group. GRADE working group. http:\/\/www.gradeworkinggroup.org\/. Date last accessed: June 19 2018."},{"key":"10.1016\/j.prrv.2018.12.001_b0055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1185\/03007995.2015.1136606","article-title":"Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004\u20132012","volume":"32","author":"Sanchez-Luna","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.prrv.2018.12.001_b0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1542\/peds.2012-3877","article-title":"Trends in bronchiolitis hospitalizations in the United States, 2000\u20132009","volume":"132","author":"Hasegawa","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2018.12.001_b0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1017\/S1047951116000470","article-title":"Respiratory syncytial virus hospitalisation trends in children with haemodynamically significant heart disease, 1997\u20132012","volume":"27","author":"Chu","year":"2017","journal-title":"Cardiol Young"},{"key":"10.1016\/j.prrv.2018.12.001_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152208","article-title":"Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997\u20132012","volume":"11","author":"Doucette","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.prrv.2018.12.001_b0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/infdis\/jiw475","article-title":"Clinical and socioeconomic burden of respiratory syncytial virus infection in children","volume":"215","author":"Heikkinen","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12887-014-0297-0","article-title":"Clinical evaluation of viral acute respiratory tract infections in children presenting to the emergency department of a tertiary referral hospital in the Netherlands","volume":"14","author":"Gooskens","year":"2014","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12879-015-1213-4","article-title":"Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged \u22645 years and its associated cost in Buenos Aires","volume":"15","author":"Marcone","year":"2015","journal-title":"Argentina. BMC Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009337","article-title":"Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK","volume":"6","author":"Taylor","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.prrv.2018.12.001_b0095","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0009922814546040","article-title":"The underrecognized burden of respiratory syncytial virus among infants presenting to US emergency departments","volume":"54","author":"Makari","year":"2015","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.prrv.2018.12.001_b0100","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2018.12.001_b0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamapediatrics.2014.3804","article-title":"Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection","volume":"169","author":"Gutfraind","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0110","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/cid\/civ331","article-title":"Reduced-dose schedule of prophylaxis based on local data provides near-optimal protection against respiratory syncytial virus","volume":"61","author":"Weinberger","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/irv.12416","article-title":"Influenza-like illness-related emergency department visits: Christmas and New Year holiday peaks and relationships with laboratory-confirmed respiratory virus detections, Edmonton, Alberta, 2004\u20132014","volume":"11","author":"Martin","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.prrv.2018.12.001_b0120","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1097\/INF.0b013e31829479d3","article-title":"Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data","volume":"32","author":"Paes","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0125","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1128\/JCM.01816-15","article-title":"Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis","volume":"53","author":"Chartrand","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.prrv.2018.12.001_b0130","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00431-014-2334-2","article-title":"Virologic testing in bronchiolitis: does it change management decisions and predict outcomes?","volume":"173","author":"Stollar","year":"2014","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jviromet.2017.01.006","article-title":"Reverse-transcription loop-mediated isothermal amplification for rapid detection of respiratory syncytial virus directly from nasopharyngeal swabs","volume":"242","author":"Hoos","year":"2017","journal-title":"J Virol Methods"},{"key":"10.1016\/j.prrv.2018.12.001_b0140","doi-asserted-by":"crossref","first-page":"e01777","DOI":"10.1128\/JCM.01777-17","article-title":"Multicenter clinical evaluation of the alere i respiratory syncytial virus isothermal nucleic acid amplification assay","volume":"56","author":"Hassan","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.prrv.2018.12.001_b0145","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1542\/peds.2014-2742","article-title":"Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis","volume":"134","author":"Ralston","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2018.12.001_b0150","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1542\/peds.2009-2345","article-title":"From the American Academy of Pediatrics: Policy statements\u2013Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections","volume":"124","author":"Committee on Infectious Diseases","year":"2009","journal-title":"Pediatrics"},{"issue":"199","key":"10.1016\/j.prrv.2018.12.001_b0155","first-page":"e1","article-title":"Comit\u00e9 de Est\u00e1ndares de la SENeo. Actualizaci\u00f3n de las recomendaciones de la Sociedad Espa\u00f1ola de Neonatolog\u00eda para la utilizaci\u00f3n del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial","volume":"82","author":"Figueras Aloy","year":"2015","journal-title":"Anales de Pediatr\u00eda"},{"key":"10.1016\/j.prrv.2018.12.001_b0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13052-015-0203-x","article-title":"Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)","volume":"41","author":"Bollani","year":"2015","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0165","first-page":"35","article-title":"Respiratory syncytial virus (RSV) prophylaxis: summary of the Austrian recommendations [German]","volume":"2","author":"Resch","year":"2009","journal-title":"P\u00e4diatrie P\u00e4dologie"},{"key":"10.1016\/j.prrv.2018.12.001_b0170","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/ped.12760","article-title":"Eligibility for palivizumab prophylaxis in a cohort of children with severe bronchiolitis","volume":"57","author":"Hasegawa","year":"2015","journal-title":"Pediatr Int"},{"key":"10.1016\/j.prrv.2018.12.001_b0175","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/INF.0000000000001150","article-title":"Association between updated guideline-based palivizumab administration and hospitalizations for respiratory syncytial virus infections","volume":"35","author":"Grindeland","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"183\u2013188","key":"10.1016\/j.prrv.2018.12.001_b0180","article-title":"Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience","volume":"181","author":"Rajah","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0185","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0037-1606352","article-title":"The 2014\u20132015 national impact of the 2014 American academy of pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States","volume":"35","author":"Kong","year":"2018","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.prrv.2018.12.001_b0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13052-017-0390-8","article-title":"The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence","volume":"43","author":"Capizzi","year":"2017","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0195","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/ANC.0000000000000367","article-title":"Evaluation of the financial and health burden of infants at risk for respiratory syncytial virus","volume":"17","author":"Blake","year":"2017","journal-title":"Adv Neonatal Care"},{"key":"10.1016\/j.prrv.2018.12.001_b0200","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2018.12.001_b0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-0036-1584147","article-title":"SENTINEL1: An observational study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks\u2019 gestational age not receiving immunoprophylaxis","volume":"34","author":"Anderson","year":"2017","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.prrv.2018.12.001_b0210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-016-0130-1","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease","volume":"5","author":"Figueras-Aloy","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.prrv.2018.12.001_b0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13052-017-0341-4","article-title":"Indications to respiratory syncytial virus immunoprophylaxis in the 29\u201332 wGA group: is there still room for debating?","volume":"43","author":"Zuccotti","year":"2017","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/INF.0000000000001377","article-title":"Burden of severe respiratory syncytial virus disease among 33\u201335 weeks' gestational age infants born during multiple respiratory syncytial virus seasons","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0225","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00431-014-2415-2","article-title":"RSV infection among children born moderately preterm in a community-based cohort","volume":"174","author":"Gijtenbeek","year":"2015","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0230","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/INF.0000000000001533","article-title":"Effectiveness of palivizumab in high-risk infants and children: A propensity score weighted regression analysis","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0235","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","volume":"4","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.prrv.2018.12.001_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059161","article-title":"Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study","volume":"8","author":"Blanken","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.prrv.2018.12.001_b0245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13052-015-0149-z","article-title":"Study Group of Italian Society of Neonatology on Risk Factors for RSV Hospitalization. Risk factors for bronchiolitis hospitalization during the first year of life in a multicentre Italian birth cohort","volume":"41","author":"Lanari","year":"2015","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0250","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/INF.0000000000000219","article-title":"Respiratory syncytial virus disease in preterm infants in the U.S. born at 32\u201335 weeks gestation not receiving immunoprophylaxis","volume":"33","author":"Ambrose","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157446","article-title":"Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI)","volume":"11","author":"Stra\u0148\u00e1k","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.prrv.2018.12.001_b0260","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ppul.23960","article-title":"Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants","volume":"53","author":"Blanken","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2018.12.001_b0265","first-page":"181","article-title":"Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland","volume":"20","author":"Borecka","year":"2016","journal-title":"Dev Period Med"},{"key":"10.1016\/j.prrv.2018.12.001_b0270","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/INF.0000000000000922","article-title":"Lanct\u00f4t KL; CARESS investigators. adherence to palivizumab for respiratory syncytial virus prevention in the canadian registry of palivizumab","volume":"34","author":"Chan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0275","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2431-14-261","article-title":"Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis","volume":"14","author":"Krilov","year":"2014","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0280","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/1471-2334-13-334","article-title":"Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis","volume":"13","author":"Stewart","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0285","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamapediatrics.2013.2636","article-title":"Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study","volume":"167","author":"Winterstein","year":"2013","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0290","doi-asserted-by":"crossref","first-page":"769","DOI":"10.4338\/ACI-2015-08-RA-0096","article-title":"Clinical decision support and palivizumab: a means to protect from respiratory syncytial virus","volume":"6","author":"Utidjian","year":"2015","journal-title":"Appl Clin Inform"},{"key":"10.1016\/j.prrv.2018.12.001_b0295","doi-asserted-by":"crossref","unstructured":"Stockton W, Chen Y, Jun A, Lee T, Murphy MC, Magedman G. Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge. Pediatr Infect Dis J. 2018 doi: 10.1097\/INF.0000000000001999. [Epub ahead of print].","DOI":"10.1097\/INF.0000000000001999"},{"key":"10.1016\/j.prrv.2018.12.001_b0300","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00431-017-2849-4","article-title":"CARESS Investigators. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005\u20132015)","volume":"176","author":"Wang","year":"2017","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0305","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1513\/AnnalsATS.201504-218OC","article-title":"Prematurity and respiratory outcomes program. comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program","volume":"12","author":"Poindexter","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.prrv.2018.12.001_b0310","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease","volume":"70","author":"Feltes","year":"2011","journal-title":"Pediatr Res"},{"key":"10.1016\/j.prrv.2018.12.001_b0315","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/CIR.0000000000000329","article-title":"Pediatric pulmonary hypertension: guidelines from the American heart association and American thoracic society","volume":"132","author":"Abman","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.prrv.2018.12.001_b0320","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0325","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/INF.0000000000001357","article-title":"Comparing first- and second-year palivizumab prophylaxis in patients with hemodynamically significant congenital heart disease in the CARESS Database (2005\u20132015)","volume":"36","author":"Li","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172512","article-title":"Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses","volume":"12","author":"Friedman","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.prrv.2018.12.001_b0335","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00246-017-1634-5","article-title":"Risk of respiratory syncytial virus hospitalization in the first and second years of life in pediatric patients with congenital heart disease","volume":"38","author":"Friedman","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.prrv.2018.12.001_b0340","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.07.020413","article-title":"Respiratory Syncytial Virus Network (ReSViNET). The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome: A systematic review and meta-analysis","volume":"7","author":"Chan","year":"2017","journal-title":"J Glob Health"},{"key":"10.1016\/j.prrv.2018.12.001_b0345","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/irv.12431","article-title":"RISK-21 Study Group. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study","volume":"11","author":"S\u00e1nchez-Luna","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.prrv.2018.12.001_b0350","doi-asserted-by":"crossref","first-page":"e531","DOI":"10.1111\/apa.13552","article-title":"Down\u2019s syndrome is a risk factor for severe lower respiratory tract infection due to respiratory syncytial virus","volume":"105","author":"Galleguillos","year":"2016","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0355","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/INF.0000000000001340","article-title":"Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in canada and italy: an international, prospective cohort study","volume":"36","author":"Manzoni","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0360","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1542\/peds.2013-3916","article-title":"Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study","volume":"133","author":"Yi","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2018.12.001_b0365","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/INF.0000000000000019","article-title":"CARESS investigators. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab","volume":"33","author":"Paes","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0370","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00431-018-3142-x","article-title":"Palivizumab use in infants with Down syndrome-report from the German Synagis\u2122 Registry 2009\u20132016","volume":"177","author":"Simon","year":"2018","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0375","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ppul.23376","article-title":"Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland","volume":"51","author":"Groves","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2018.12.001_b0380","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ppul.22711","article-title":"Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis","volume":"48","author":"Winterstein","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2018.12.001_b0385","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/INF.0000000000001501","article-title":"Respiratory syncytial virus infection-associated hospitalization rates in infants and children with cystic fibrosis","volume":"36","author":"Metz","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0390","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10096-018-3256-0","article-title":"Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005\u20132016)","volume":"37","author":"Mitchell","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0395","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s10096-018-3225-7","article-title":"Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?","volume":"37","author":"Bjornson","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0400","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1936","article-title":"Systematic review of the safety and efficacy of palivizumab among infants and young children with cystic fibrosis","volume":"37","author":"Kua","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.prrv.2018.12.001_b0405","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.aller.2013.09.003","article-title":"Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis","volume":"43","author":"S\u00e1nchez-Solis","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.prrv.2018.12.001_b0410","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40121-017-0151-4","article-title":"The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood","volume":"6","author":"Fauroux","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.prrv.2018.12.001_b0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125422","article-title":"IRIS (Infecci\u00f3n Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-The SPRING Study","volume":"10","author":"Carbonell-Estrany","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.prrv.2018.12.001_b0420","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S2213-2600(18)30055-9","article-title":"Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial","volume":"6","author":"Scheltema","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2018.12.001_b0425","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1164\/rccm.201604-0753OC","article-title":"A distinct low lung function trajectory from childhood to the fourth decade of life","volume":"194","author":"Berry","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2018.12.001_b0430","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1542\/peds.2013-1131","article-title":"Late preterm infants: near term but still in a critical developmental time period","volume":"132","author":"Kugelman","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2018.12.001_b0435","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1542\/peds.2013-0982","article-title":"C-CREW Investigators. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants","volume":"132","author":"Yoshihara","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2018.12.001_b0440","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1164\/rccm.201609-1812OC","article-title":"Scientific committee for elucidation of infantile asthma. Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study","volume":"196","author":"Mochizuki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2018.12.001_b0445","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpeds.2015.11.040","article-title":"Have changing palivizumab administration policies led to more respiratory morbidity in infants born at 32\u201335 Weeks?","volume":"171","author":"Olicker","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0450","first-page":"ofy031","article-title":"Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value. Open forum","volume":"5","author":"Olchanski","year":"2018","journal-title":"Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0455","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3111\/13696998.2012.734886","article-title":"The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence","volume":"16","author":"Hussman","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.prrv.2018.12.001_b0460","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00431-017-3046-1","article-title":"Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants","volume":"177","author":"Blanken","year":"2018","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.prrv.2018.12.001_b0465","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12879-017-2803-0","article-title":"Cost-utility analysis of palivizumab for respiratory syncytial virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain","volume":"17","author":"Sanchez-Luna","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.prrv.2018.12.001_b0470","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/INF.0b013e3181710990","article-title":"IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks","volume":"27","author":"Figueras-Aloy","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0475","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0b013e318235455b","article-title":"Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria","volume":"31","author":"Resch","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.prrv.2018.12.001_b0480","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ppul.22906","article-title":"Pediatricians\u2019 attitudes and costs of bronchiolitis in the emergency department: a prospective multicentre study","volume":"49","author":"Garcia-Marcos","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2018.12.001_b0485","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/apa.14224","article-title":"Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS])","volume":"107","author":"Carbonell-Estrany","year":"2018","journal-title":"Acta Paediatr"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054218301398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054218301398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:35:04Z","timestamp":1761507304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054218301398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":97,"alternative-id":["S1526054218301398"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2018.12.001","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus on palivizumab use for respiratory syncytial virus in developed countries","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}